Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patidegib Gel 2% for Facial Basal Cell Carcinoma Prevention in Adults With Gorlin Syndrome
2023-507528-21-00Phase 3Completed
- Sponsor
- Sol-Gel Technologies
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in Basal cell nevus syndrome (BCNS) and basal cell carcinoma (BCC) comparing Patidegib Gel 2% with Vehicle Gel (2 arms). Started May 2024; status: completed.
02
Drugs
patidegib
03
Conditions
Basal cell nevus syndrome (BCNS)basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2023-507528-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507528-21-00.